thymosin beta-4 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
Eannatum (Sumerian: 𒂍𒀭𒈾𒁺 É.AN.NA-tum2; fl. c. 2450 BC) was a Sumerian Ensi (ruler or king) of Lagash. He established one of the first verifiable empires in history, subduing Elam and destroying the city of Susa, and extending his domain over the rest of Sumer and Akkad. One inscription found on a boulder states that Eannatum was his Sumerian name, while his "Tidnu" (Amorite) name was Lumma.
== Awards and honours == Hopkins was elected a Foreign Associate of the National Academy of Sciences (USA) in 1924. During his life, in addition to the Nobel Prize, Hopkins was awarded the Royal Medal of the Royal Society in 1918, the Cameron Prize for Therapeutics of the University of Edinburgh in 1922, and the Copley Medal of the Royal Society in 1926. Other significant honours were his election in 1905 as a Fellow of the Royal Society (FRS), Great Britain's most prestigious scientific organisation; his knighthood by King George V in 1925; and the award in 1935 of the Order of Merit, Great Britain's most exclusive civilian honour. From 1930 to 1935, he served as president of the Royal Society and, in 1933, served as president of the British Association for the Advancement of Science. He was elected to the American Philosophical Society in 1937.
=== Other neurological disorders === Tourette syndrome. The available data was determined to be insufficient to allow reliable conclusions to be drawn regarding the effectiveness of oral cannabis extract or THC in controlling tics. Cervical dystonia. Insufficient data was available to assess the effectiveness of oral cannabis extract of THC in treating cervical dystonia.
Sources: en.wikipedia.org
== External links == "Paclitaxel". National Cancer Institute. 5 October 2006. "Paclitaxel". NCI Drug Dictionary. 2 February 2011. Molecule of the Month: TAXOL by Neil Edwards, University of Bristol. A Tale of Taxol from Florida State University. Berenson A (1 October 2006). "Hope, at $4,200 a Dose". The New York Times. Retrieved 31 March 2007.
Preclinical research suggests that several derivatives of aromatic amino acids with antiglutamatergic properties including AMPA receptor antagonism and inhibition of glutamate release such as 3,5-dibromo-D-tyrosine and 3,5-dibromo-L-phenylalnine exhibit strong anticonvulsant effect in animal models suggesting use of these compounds as a novel class of antiepileptic drugs.
== Summary == Following several years of unsuccessful petitioning through the United Nations and the International Court of Justice for Namibian independence from South Africa, SWAPO formed the PLAN in 1962 with material assistance from the Soviet Union and sympathetic African states such as Tanzania, Ghana, and Algeria. Fighting broke out between PLAN and the South African security forces in August 1966. Between 1975 and 1988, the SADF staged massive conventional raids into Angola and Zambia to eliminate PLAN's forward operating bases. It also deployed specialist counter-insurgency units such as Koevoet and 32 Battalion, trained to carry out external reconnaissance and track guerrilla movements. South African tactics became increasingly aggressive as the conflict progressed. The SADF's incursions produced Angolan casualties and occasionally resulted in severe collateral damage to economic installations regarded as vital to the Angolan economy. Ostensibly to stop these raids, but also to disrupt the growing alliance between the SADF and the National Union for the Total Independence of Angola (UNITA), which the former was arming with captured PLAN equipment, the Soviet Union backed the People's Armed Forces of Liberation of Angola (FAPLA) through a large contingent of military advisers, along with up to four billion dollars' worth of modern defence technology in the 1980s. Beginning in 1984, regular Angolan units under Soviet command were confident enough to confront the SADF. Their positions were also bolstered by thousands of Cuban troops.
The 'a' in DTaP and Tdap stands for 'acellular', meaning that the pertussis component contains only a part of the pertussis organism." Another list of established vaccine abbreviations is at the CDC's page called "Vaccine Acronyms and Abbreviations", with abbreviations used on U.S. immunization records. The United States Adopted Name system has some conventions for the word order of vaccine names, placing head nouns first and adjectives postpositively. This is why the USAN for "OPV" is "poliovirus vaccine live oral" rather than "oral poliovirus vaccine".
Sources: en.wikipedia.org
On the 20th anniversary in November 2024, Valve made Half-Life 2 temporarily free on Steam and updated it to incorporate Episode One, Episode Two and Lost Coast, improve graphics and controls, restore lost content, fix bugs and add developer commentary. Half-Life 2 reached a new peak of 64,085 concurrent players on Steam, surpassing the previous record of 16,101 in August 2021. Valve also released a two-hour making-of documentary.
=== Terminology === Valproate is a negative ion. The conjugate acid of valproate is valproic acid (VPA). Valproic acid is fully ionized into valproate at the physiologic pH of the human body, and valproate is the active form of the drug. Sodium valproate is the sodium salt of valproic acid. Divalproex sodium is a coordination complex composed of equal parts of valproic acid and sodium valproate.
Two days later, the most serious event occurred: "ultras" gunmen burst into the office of some labor lawyers linked to the Comisiones Obreras and the Communist Party, located in Atocha street in Madrid, and put against the wall eight of them and a janitor, shooting then. Five members of the firm died on the spot and four others were seriously wounded. But the 1977 Atocha massacre did not achieve its objective of creating a climate evoking the civil war. On the contrary, it raised a wave of solidarity with the Communist Party, which gathered in the streets an orderly and silent crowd to attend the burial of the murdered communist militants. The Army, therefore, had no reason to intervene and not even the government decreed a state of emergency, as claimed by the extreme right. And when it seemed that the crisis had been overcome the GRAPO reappeared, who like the extreme right also wanted to stop the process of political transition, and kidnapped the president of the Supreme Council of Military Justice, General Emilio Villaescusa Quilis ─ while they still held Antonio María de Oriol, president of the Council of State, hostage ─ and killed three policemen. But neither the Suárez government nor the Army fell for the provocation on this occasion either.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.